2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed models
2023
Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effect